At Fagus Therapeutics, we are dedicated to addressing the health challenges associated with ageing. As we get older, the risk of developing conditions like arthritis, osteoporosis, and diabetes increases, impacting our quality of life and placing a growing strain on healthcare systems worldwide.
We aim to identify and target senescent cells using antibodies that specifically recognise them. These antibodies can deliver a drug that induces the cells to die using natural processes. By doing so, we can potentially alleviate the burden of age-related diseases on individuals and healthcare services.
The team brings together researchers who collectively have over 70 years of scientific expertise.
Dr Gulam Altab
Dr Gulam Altab
Dr. Gulam Altab (BSc, MSc, MRes, and PhD) is a dedicated researcher specialising in the ageing of skeletal muscle and its response to caloric restriction. His PhD thesis focused on understanding the intricate changes in non-coding RNAs that occur during muscle ageing in rats. During this research, he aimed to identify key regulatory elements and biomarkers, with a specific focus on whether these changes could be influenced by dietary interventions, especially caloric restriction.
Gulam’s academic journey includes an MSc in Stem Cells and Regenerative Medicine and an MRes in Musculoskeletal Ageing. He has extensive experience in various research techniques and methodologies, including RNA sequencing, single-cell analysis, and molecular biology. He possesses a deep understanding of the complex cellular pathways and molecular mechanisms that underlie the ageing of tissues.
Currently, Gulam is deeply interested in the potential of targeted anti-ageing therapeutics. He firmly believes that slowing the ageing process is not only about extending our years but also enhancing the quality of our lives. It represents a journey towards a healthier, more fulfilling future.
“Slowing the ageing process is not just about increasing our lifespan; it’s an opportunity to improve our quality of life. It’s a path towards a healthier, more rewarding future.”
Fatima Aitbenhaddou is a scientist with more than 22 years of expertise in life sciences management. She has worked for renowned global companies, gaining industry experience in Immunology technical methods, including Hybridoma cell line development, antibody manufacturing processes, Immunoassay development, Bioconjugation of protein and antibody, as well as Analytical and biochemical techniques. Fatima’s extensive knowledge and independent lab experience make her an ideal candidate to lead research and innovation in this field.
Umar is a founder member and the Chief Financial Officer of Fagus Therapeutics. He has a plethora of expertise working in the financial services industry, equipped with a solid foundation in accounting. Umar will be responsible for managing the company’s finances and strategically accelerating growth thanks to his broad range of financial talents, entrepreneurial enthusiasm, and organisational abilities.
Gulam Ahmed LLB (Hons) LLM Since being called to the bar in 1997, Gulam Ahmed has been practising as a specialist criminal barrister. This has included homicide, terrorism and fraud. Over the years, Gulam Ahmed has defended in some of the highest profile cases attracting media attention. His dedication, strong advocacy skills and analytical ability have made him successful and placed him very much in demand. Gulam Ahmed is a founder member of Fagus and its Chairman. Although he remains in independent practice, Gulam Ahmed guides Fagus’s board on business strategy, governance, delivery of services and products, and finance. Gulam Ahmed plays an integral role with the board in growing Fagus whilst maintaining quality and excellence.
Gustavo Daniel Vega Magdaleno
Gustavo Daniel Vega Magdaleno
Board of Advisors
Prof. João Pedro de Magalhães
João Pedro de Magalhães
Prof de Magalhaes graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and then obtained his PhD in 2004 from the University of Namur in Belgium. Following a postdoc with genomics pioneer Prof George Church at Harvard Medical School in Boston, USA, in 2008 Prof de Magalhaes was recruited to the University of Liverpool in the UK to establish his own group on genomic approaches to ageing. In 2022, Prof de Magalhaes was recruited to the University of Birmingham as Chair of Molecular Biogerontology where he currently leads the Genomics of Ageing and Rejuvenation Lab [http://rejuvenomicslab.com/].
His lab studies the ageing process and how we can manipulate it to fend off age-related diseases and improve human health. The lab’s research integrates different strategies, but its focal point is developing and applying experimental and computational methods that help bridge the gap between genotype and phenotype, a major challenge of the post-genome era, and help decipher the human genome and how it regulates complex processes like ageing.
Notably, his lab is a world-leader in employing genomics and bioinformatics to study ageing with pioneering work in studying gene networks of ageing and in sequencing and analysing genomes from long-lived species. Prof de Magalhaes has authored over 100 publications and given over 100 invited talks, including three TEDx talks. His research has also been widely featured in the popular press (BBC, CNN, the Washington Post, the Financial Times and many others).